By Scott Power
01 July 2021, 4:00 PM
Nanosonics (ASX:NAN) has launched a new digital platform, AuditPro™ offering digital traceability, reporting and compliance providing a new revenue stream which we think has good potential.
Read more...
By Dr Derek Jellinek
03 June 2021, 9:30 AM
Peter Rowland, Managing Director of Micro-X (MX1) explains the significance of the next generation X-ray technology for global health and security markets.
Read more...
By Dr Derek Jellinek
31 May 2021, 8:00 AM
Senior Analyst Dr. Derek Jellinek updates on stocks in the Healthcare sector such as Ramsay Healthcare, Resmed, Sonic Healthcare, Ansell, CSL, and Volpara Health Technologies.
Read more...
By Dr Derek Jellinek
28 April 2021, 4:50 PM
Ongoing elevated demand for PPE and product supply on track to meet that
demand saw the company provide a favourable trading update and upgrade
guidance, again.
Read more...
By Scott Power
15 April 2021, 8:00 AM
Morgans Senior Analyst Scott Power speaks with Chief Executive Officer of Control Bionics, Rob Wong, on the significant progress the healthcare company is making.
Read more...
By Scott Power
12 April 2021, 3:30 PM
Mach7 Technologies 3QFY21 result has restored investor confidence. Pleasingly, A$12.8m in new sales orders were generated for the quarter.
Read more...
By Iain Wilkie
30 March 2021, 4:00 PM
Morgans analyst Iain Wilkie speaks with Chief Executive Officer and Managing Director of ResApp (ASX:RAP), Tony Keating. Tony provides an update on a number of recent news events.
Read more...
By Scott Power
18 March 2021, 11:15 AM
Volpara has announced its largest contract to date worth over US$400,000. The next catalyst will be an increasing ARPU to be reported in the 4QFY21 cashflow report.
Read more...
By Dr Derek Jellinek
15 March 2021, 3:10 PM
While we make no changes to our estimates or price target, we believe CSL share weakness offers an opportunity to buy a high-quality business at a discount.
Read more...
By Dr Derek Jellinek
18 February 2021, 4:30 PM
In CSL Ltd's 1H21 results, Seqirus was the standout on pandemic driven demand for influenza vaccines, while Behring gained from Albumin sales and cost-outs, but Ig growth was modest and Specialty /Haemophilia fairly flat.
Read more...